Autoplaque vs FEops HEARTguideTM
AI Verdict
Choose Autoplaque if…
Choose Autoplaque if your primary need is detailed, AI-powered quantitative analysis of coronary plaques and luminal stenoses from CT angiography images. This workstation-based software is ideal for clinicians focused on early detection, risk stratification, and guiding treatment strategies for coronary artery disease based on precise plaque characterization.
View Autoplaque →Choose FEops HEARTguideTM if…
Choose FEops HEARTguideTM if you require advanced, AI-driven predictive simulations and anatomical insights for planning complex structural heart interventions such as TAVI or LAAO. This cloud-based platform is best suited for optimizing device sizing and positioning, ensuring precise pre-procedural planning to improve patient outcomes.
View FEops HEARTguideTM →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Autoplaque | FEops HEARTguideTM |
|---|---|---|
| Pricing | Unknown | Contact for pricing |
| Deployment | Workstation-based post-processing application, runs on Windows or Mac OS. | Cloud-based |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Unknown | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
FEops HEARTguideTMFEops HEARTguide (Tool B) offers superior usability due to its cloud-based platform, providing access from anywhere at any time. It also features a DICOM interface for seamless integration into existing clinical workflows and is described as intuitive and easy to use. In contrast, Autoplaque (Tool A) is workstation-based, which can be less flexible in modern healthcare environments.
Clinical Value
FEops HEARTguideTMBoth tools are FDA-cleared and offer significant clinical value. However, FEops HEARTguide (Tool B) has demonstrated a more direct impact on procedural efficiency and patient outcomes through the PREDICT-LAA randomized clinical trial, showing improved LAAO procedure outcomes and reduced complications. Autoplaque (Tool A) provides valuable plaque analysis for risk prediction, but Tool B's evidence of improving complex interventional procedures gives it a stronger clinical outcome-driven advantage.
Pricing & Value
TieBoth Autoplaque (Tool A) and FEops HEARTguide (Tool B) have undisclosed pricing, making a direct comparison of their value proposition impossible. While Tool B explicitly mentions a service-based business model, which could offer flexibility, without concrete pricing for either, a definitive winner cannot be determined.
Enterprise Readiness
FEops HEARTguideTMFEops HEARTguide (Tool B) is clearly more enterprise-ready, explicitly stating HIPAA compliance and the availability of a Business Associate Agreement (BAA). Its cloud-based deployment, DICOM interface for integration, and partnerships with companies like TeraRecon further enhance its suitability for large healthcare systems. Autoplaque (Tool A) is workstation-based and does not specify HIPAA compliance or BAA availability, posing potential challenges for enterprise adoption.
Innovation
FEops HEARTguideTMFEops HEARTguide (Tool B) demonstrates a higher level of innovation with its 'digital twin platform' and 'predictive simulation technology' for device-anatomy interaction in structural heart procedures. This capability allows for pre-operative simulation and optimization of interventions, pushing beyond diagnostic analysis. Tool B has also received industry recognition and awards for its innovative approach.
Support & Docs
FEops HEARTguideTMFEops HEARTguide (Tool B) provides a dedicated support email address ([email protected]) and mentions support for security features like multi-factor authentication. In contrast, for Autoplaque (Tool A), only general Cedars-Sinai contact information is readily available, with no specific product support channels identified.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Autoplaque | FEops HEARTguideTM |
|---|---|---|
| Name | Autoplaque | FEops HEARTguideTM |
| Company | Cedars-Sinai Medical Center: AIM | FEops nv |
| Description | Autoplaque, developed by Cedars-Sinai AIM, is an FDA-cleared AI-powered software for quantitative analysis of coronary plaques and luminal stenoses from CT angiography images, aiding in heart attack risk prediction and treatment guidance. | FEops HEARTguideu2122 is a cloud-based AI and digital twin platform for structural heart procedure planning, providing predictive simulations and anatomical insights to optimize device sizing and positioning for interventions like TAVI and LAAO. |
| Key Features | AI-powered quantitative analysis of atherosclerotic plaque; Detection and characterization of coronary artery plaque; Measurement of luminal stenoses; Analysis of coronary anatomy and pathology from CT Angiographic images; Workstation-based post-processing application; Automated vessel, plaque, and lumen segmentation (reviewable and editable by clinician); Review of heart and coronary vessels in Multiplanar Reformatting (MPR), curved MPR, and straightened MPR views; Measurement of vessel diameter and area | Predictive simulation technology for device-anatomy interaction; AI-based anatomical measurements from CT scans; Cloud-based platform with access from anywhere at any time; DICOM interface for easy integration into clinical workflow; Semi-automatic and manual measurement options for anatomical landmarks; Interactive 2D and 3D viewer for detailed analysis; Segmentation of cardiovascular structures; Visualization and image reconstruction techniques (2D review, MPR) |
| Specialties | Cardiology, Radiology | Cardiology, Cardiothoracic Surgery, Radiology |
Videos
Demos, reviews, and walkthroughs featuring Autoplaque and FEops HEARTguideTM.